Given the potential therapeutic use of IFN-β (37, 38), and the absence of IFN-β-neutralization data for COVID-19 patients, we tested a larger number of patients and controls, including patients without auto-Abs against IFN-α or IFN-ω, for auto-Abs against IFN-β, assessing the levels and neutralizing activity of auto-Abs against 10 ng/mL IFN-β. The gene discussed is IFNA1; the disease is COVID-19.